Fertility preservation with ovarian stimulation protocols prior to cancer treatment

References

• Hamilton BE, Martin JA, Ventura SJ. Births: preliminary datafor 2011. In: National vital statistics reports web release, vol. 61, no. 5. Hyattsville, MD: National Center for Health Statistics; 2012
   Google Scholar
• Howlader N, Noone AM, Krapch M, et al. (eds.). SEER cancer statistics review, 1975–2009 (vintage 2009 populations). Bethasda, MD. National Cancer Institute. Available at: http://seer.cancer.gov/csr/1975_2009_pops09/. [last accessed 16 Dec 2012]
   Google Scholar
• Letourneau JM, Ebbel EE, Katz PP, et al. Pretreatment fertility counseling and fertility preservation improve quality of life in reproductive age women with cancer. Cancer 2012;118:1710–17
   PubMed Web of Science ®Google Scholar
• Letourneau JM, Ebbel EE, Katz PP, et al. Acute ovarian failure underestimates age-specific reproductive impairment for young women undergoing chemotherapy for cancer. Cancer 2012;118:1933–9
   PubMed Web of Science ®Google Scholar
• Wyns C. Fertility preservation: current prospects and future challenges. Gynecol Endocrinol 2013;29:403–7
   PubMed Web of Science ®Google Scholar
• Meirow D, Biederman H, Andersom RA, Walace WH. Toxicity of chemotherapy and radiation on female reproduction. Clin Obstet Gynecol 2010;53:727–9
   PubMed Web of Science ®Google Scholar
• Morice P, Uzan C, Gouy S, et al. Effects of radiotherapy (external and/or internal) and chemotherapy on female fertility. Bull Acad Natl Med 2010;194:481–92
   PubMedGoogle Scholar
• Wo JY, Shipley WU, Dahl DM, et al. Impact of radiotherapy on fertility, pregnancy, and neonatal outcomes in female cancer patients. BJU Int 2009;104:179–83
   PubMedGoogle Scholar
• Grynberg M, Poulain M, Le Parco S, et al. How to preserve female fertility before cancer treatments?. Rev Prat 2013;63:314–18
   PubMedGoogle Scholar
• Loren AW, Mangu PB, Beck LN, et al. Fertility preservation for patients with cancer: american society of clinical oncology clinical practice guideline update. J Clin Oncol 2013;31;2500--10
   PubMed Web of Science ®Google Scholar
• Das M, Shehata F, Moria A, et al. Ovarian reserve, response to gonadotropins, and oocyte maturity in women with malignancy. Fertil Steril 2011;96:122–5
   PubMedGoogle Scholar
• Friedler S, Koc O, Gidoni Y, et al. Ovarian response to stimulation for fertility preservation in women with malignant disease: a systematic review and meta-analysis. Fertil Steril 2012;97:125–33
   PubMed Web of Science ®Google Scholar
• Lawrenz B, Fehm T, von Wolff M, et al. Reduced pretreatment ovarian reserve in premenopausal female patients with Hodgkin lymphoma or non-Hodgkin-lymphoma – evaluation by using antimüllerian hormone and retrieved oocytes. Fertil Steril 2012;98:141–4
   PubMed Web of Science ®Google Scholar
• Ebbel E, Katz A, Kao CN, et al. Reproductive aged women with cancer have a lower antral follicle count than expected. Fertil Steril 2011;96:S199–200
   Google Scholar
• Cakmak H, Rosen MP. Ovarian stimulation in cancer patients. Fertil Steril 2013;99:1476–84
   PubMed Web of Science ®Google Scholar
• Humaidan P, Bungum L, Bungum M, et al. Reproductive outcome using a GnRH antagonist (cetrorelix) for luteolysis and follicular synchronization in poor responder IVF/ICSI patients treated with a flexible GnRH antagonist protocol. Reprod Biomed Online 2005;11:679–84
   PubMed Web of Science ®Google Scholar
• Cakmak H, Zamah AM, Katz A, et al. Effective method for emergency fertility preservation: random-start controlled ovarian hyperstimulation. Fertil Steril 2012;98:S 170–8
   Google Scholar
• von Wolff M, Thaler CJ, Frambach T, et al. Ovarian stimulation to cryopreserve fertilized oocytes in cancer patients can be started in the luteal phase. Fertil Steril 2009;92:1360–5
   PubMed Web of Science ®Google Scholar
• Reddy J, Oktay K. Ovarian stimulation and fertility preservation with the use of aromatase inhibitors in women with breast cancer. Fertil Steril 2012;98:1363–9
   PubMed Web of Science ®Google Scholar
• Rodriguez-Walberg KA, Oktay K. Fertility preservation in women with breast cancer. Clin Obstet Gynecol 2010;53:753–62
   PubMed Web of Science ®Google Scholar
• Oktay K, Buyuk E, Davis O, et al. Fertility preservation in breast cancer patients: IVF and embryo cryopreservation after ovarian stimulation with tamoxifen. Hum Reprod 2003;18:90–5
   PubMed Web of Science ®Google Scholar
• Oktay K, Buyuk E, Libertella L, et al. Fertility preservation in breast cancer patients: a prospective controlled comparison of ovarian stimulation with tamoxifen and letrozole for embryo cryopreservation. J Clin Oncol 2005;23:4347–53
   PubMed Web of Science ®Google Scholar
• Thurlimann B, Keshaviah A, Coates AS, et al. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 2005;353:2747–57
   PubMed Web of Science ®Google Scholar
• Oktay K, Hourvitz A, Oktem O, et al. Letrozole reduces estrogen and gonadotropin exposure in women with breast cancer undergoing ovarian stimulation before chemotherapy. J Clin Endocrinol Metab 2006;91:3885–90
   PubMed Web of Science ®Google Scholar
• Johnson LN, Dillon KE, Sammel MD, et al. Response to ovarian stimulation in patients facing gonadotoxic therapy. Reprod Biomed Online 2013;26:337–44
   PubMed Web of Science ®Google Scholar
• Azemi AA, Constantini-Ferrando M, Oktay K. Safety of fertility preservation by ovarian stimulation with letrozole and gonadotropins in patients with breast cancer: a prospective controlled study. J Clin Oncol 2008;26:2630–5
   PubMedGoogle Scholar
• Azim A, Oktay K. Letrozole for ovulation induction and fertility preservation by embryo cryopreservation in young women with endometrial carcinoma. J Clin Oncol 2008;26:2630–5
   PubMed Web of Science ®Google Scholar
• Tiboni GM. Aromatase inhibitors and teratogenesis. Fertil Steril 2004;81:1158–9
   PubMed Web of Science ®Google Scholar
• Azim AA, Constantini-Ferrando M, Lostrito K, Oktay K. Relative potencies of anastrozole and letrozole to suppress estradiol in breast cancer patients undergoing ovarian stimulation before in vitro fertilization. J Clin Endocrinol Metabol 2007;92:2197–200
   PubMed Web of Science ®Google Scholar
• Engmann L, DiLuigi A, Schmidt D, et al. The use of gonadotropin-releasing hormone (GnRH) agonist to induce oocyte maturation after cotreatment with GnRH antagonist in high-risk patients undergoing in vitro fertilization prevents the risk of ovarian hyperstimulation syndrome: a prospective randomized controlled study. Fertil Steril 2008;89:84–91
   PubMed Web of Science ®Google Scholar
• Ou YC, Kao YL, Lai SL, et al. Thromboembolism after ovarian stimulation: successful management of a woman with superior sagittal sinus thrombosis after IVF and embryo transfer: case report. Hum Reprod 2003;18:2375–81
   PubMed Web of Science ®Google Scholar
• Yinon Y, Pauzner R, Dulitzky M, et al. Safety of IVF under anticoagulant therapy in patients at risk for thrombo-embolic events. Reprod Biomed Online 2006;12:354–8
   PubMed Web of Science ®Google Scholar